Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • New USFDA warning...

    New USFDA warning letters show Glenmark, Lupin, Cadila Healthcare in trouble

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-11-07T16:20:51+05:30  |  Updated On 17 Aug 2021 10:46 AM IST

    Cadila Healthcare Ltd., Glenmark Pharmaceuticals Ltd. and Lupin Ltd. are the latest local medicine makers to be reprimanded by the US Food and Drug Administration, exchange filings show.


    New Delhi: Three major Indian drugmakers received warning letters from the US health care watchdog in the last two months, highlighting that the country's copycat drug sector is still plagued by quality issues amid rising global concern over tainted drug supplies.


    Cadila Healthcare Ltd., Glenmark Pharmaceuticals Ltd. and Lupin Ltd. are the latest local medicine makers to be reprimanded by the US Food and Drug Administration, exchange filings show. A plant with a warning letter is barred from introducing new products in the US, stymieing the company's ability to grow revenue in the world's top pharmaceutical market.


    The latest regulatory crackdown shows the US regulator's stance is hardening toward lapses in quality control even as it seeks cheaper drugs to contain health care costs. Indian pharmaceutical factories collectively produce about 40 per cent of the American generic drug supply and have been faulted in the past by the FDA for everything from lax documentation to open toilet drains and malfunctioning equipment.


    Read Also: Zydus Cadila receives warning letter from USFDA for Moraiya-based formulation facility


    The USFDA is struggling to contain the damage after carcinogenic chemicals were discovered in generic drugs to control blood pressure and stomach acid, prompting drug makers in India and elsewhere to recall the medicines.


    Cadila Healthcare received a warning letter against its Moraiya facility in the western state of Gujarat, it said in a Nov. 4 filing, about three years after a previous warning letter against this plant was lifted.


    Glenmark told exchanges in October that its manufacturing site in Baddi in Himachal Pradesh has got a similar letter, without elaborating on the reasons for this regulatory action. Lupin informed investors Sept. 19 that its Mandideep plant had also got a warning letter. The US FDA said it had found similar quality control lapses at Lupin's two other sites too.


    By Ari Altstedter


    Read Also: Torrent Pharma shares slump 3pc on USFDA warning letter for Gujarat facility

    Baddi plantCadilaCadila HealthcarecancercarcinogenicGlenmarkGlenmark PharmaHealthcareIndian pharma factories​LupinMandideep facilityMoraiya facilitypharmapharma companypharma newsUSFDAUSFDA warningwarning letters
    Source : Bloomberg

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok